Marc Hulsman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marc Hulsman has a total of 890 co-authors. Here are the top co-authors by number of shared publications:
- Henne Holstege
Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands
18 shared publications - Wiesje Maria van der Flier
Neurodegeneration, Amsterdam Neuroscience, Amsterdam, Netherlands
11 shared publications - Niccoló Tesi
Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands
10 shared publications - Alfredo Ramirez
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
8 shared publications - Jean-Charles Lambert
Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
8 shared publications - Oriol Dols-Icardo
Sant Pau Memory Unit, Neurology Department, IR Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
8 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Springer Nature in Nature
- p. 1-12
Alzheimer’s disease genetics converges on microglial and neuronal dysregulation
Alzheimer’s disease (AD) is the most common cause of dementia, with global case numbers projected to reach 153 million in 20501. AD is highly heritable, with twin-based heritability estimates of 60–80%2. Although 1,200 causal loci are predicted to exist for AD3, approximately 80 loci have been associated with AD in two recent studies4,5. Low single-nucleotide polymorphism (SNP)-based heritability estimates have prompted the suggestion that little further common-variant risk remains to be found6. Here we analysed data from 109,479 cases, 74,141 proxy cases, 2,131,799 controls and 499,708 proxy controls from diverse ancestries, identifying 118 loci in a multi-ancestry analysis and 9 additional loci in ancestry-specific analyses, 48 of which are new. We identified new AD risk genes, prioritized potential drug targets, and found that genes upregulated in microglia and downregulated in neurons in cases compared with controls were enriched for AD-associated genetic risk. Moreover, we improved polygenic prediction and estimated a SNP heritability of 16%, nearly threefold higher than previous estimates. Together, our findings show that the common-variant contribution to AD has been substantially underestimated, and reveal new molecular and cellular mechanisms as well as specific targets for future drug development research.
- 28 October 2026
- Published by Springer Nature in Nature
- p. 1-12
Open AccessAlzheimer’s disease genetics converges on microglial and neuronal dysregulation
Alzheimer’s disease (AD) is the most common cause of dementia, with global case numbers projected to reach 153 million in 20501. AD is highly heritable, with twin-based heritability estimates of 60–80%2. Although 1,200 causal loci are predicted to exist for AD3, approximately 80 loci have been associated with AD in two recent studies4,5. Low single-nucleotide polymorphism (SNP)-based heritability estimates have prompted the suggestion that little further common-variant risk remains to be found6. Here we analysed data from 109,479 cases, 74,141 proxy cases, 2,131,799 controls and 499,708 proxy controls from diverse ancestries, identifying 118 loci in a multi-ancestry analysis and 9 additional loci in ancestry-specific analyses, 48 of which are new. We identified new AD risk genes, prioritized potential drug targets, and found that genes upregulated in microglia and downregulated in neurons in cases compared with controls were enriched for AD-associated genetic risk. Moreover, we improved polygenic prediction and estimated a SNP heritability of 16%, nearly threefold higher than previous estimates. Together, our findings show that the common-variant contribution to AD has been substantially underestimated, and reveal new molecular and cellular mechanisms as well as specific targets for future drug development research.
- Open Access
Plasma neurofilament light links mortality to neuroaxonal injury beyond clinical decline and Alzheimer disease plasma biomarkers: a multi-cohort study of oldest old individuals
Blood-based neurofilament light (NfL) is associated with all-cause mortality, but whether this reflects neuroaxonal injury or overlaps with cognitive and functional decline remains unclear. We followed 559 individuals aged 92–107 from three oldest-old cohorts for up to 16 years: cognitively healthy Dutch centenarians and two population-based Danish cohorts. Plasma biomarkers (Aβ 42/40 , Aβ 40 , Aβ 42 , pTau-181, pTau-181/Aβ 42 , NfL, and GFAP; Dutch cohort; NfL, Danish cohorts), cognition, and activities of daily living (ADL) were evaluated against mortality. NfL was the only biomarker consistently associated with mortality (HR 1.21–1.38), whereas AD-specific biomarkers did not predict mortality despite reflecting post-mortem AD neuropathology. NfL remained associated with mortality independently of cognition and ADL; ADL mediated 13–21% across cohorts and cognition 28%, only where cognitive impairment was widespread. Mortality at extreme age is more closely linked to neuroaxonal injury than to upstream AD pathology, with NfL capturing biological vulnerability beyond cognitive and functional decline.
Open AccessPlasma neurofilament light links mortality to neuroaxonal injury beyond clinical decline and Alzheimer disease plasma biomarkers: a multi-cohort study of oldest old individuals
Blood-based neurofilament light (NfL) is associated with all-cause mortality, but whether this reflects neuroaxonal injury or overlaps with cognitive and functional decline remains unclear. We followed 559 individuals aged 92–107 from three oldest-old cohorts for up to 16 years: cognitively healthy Dutch centenarians and two population-based Danish cohorts. Plasma biomarkers (Aβ 42/40 , Aβ 40 , Aβ 42 , pTau-181, pTau-181/Aβ 42 , NfL, and GFAP; Dutch cohort; NfL, Danish cohorts), cognition, and activities of daily living (ADL) were evaluated against mortality. NfL was the only biomarker consistently associated with mortality (HR 1.21–1.38), whereas AD-specific biomarkers did not predict mortality despite reflecting post-mortem AD neuropathology. NfL remained associated with mortality independently of cognition and ADL; ADL mediated 13–21% across cohorts and cognition 28%, only where cognitive impairment was widespread. Mortality at extreme age is more closely linked to neuroaxonal injury than to upstream AD pathology, with NfL capturing biological vulnerability beyond cognitive and functional decline.
- Open Access
- 14 August 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (9) , 2164-2176
PLCG2 downregulation impairs synaptic function and increases Alzheimer’s disease hallmarks in neuronal cultures
- 14 August 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (9) , 2164-2176
Open AccessPLCG2 downregulation impairs synaptic function and increases Alzheimer’s disease hallmarks in neuronal cultures
- Top Cited PapersOpen Access
- 4 June 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (6) , 2047-2059
Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience
Alzheimer’s disease (AD) is not an inevitable outcome of pathology but a dynamic process shaped by how brain cells respond to amyloid-β (Aβ) and tau. To disentangle these responses, we combined spatial transcriptomics and single-nucleus RNA sequencing of the superior frontal cortex from octogenarians living with or without dementia and from cognitively intact centenarians with comparable Aβ accumulation. We identified six distinct tissue domains representing a spatial pathological continuum of AD, with a key inflection point marked by a shift from Aβ-associated inflammatory changes to tau-associated cellular programs. This transition was accompanied by a change in microglial states, from early inflammatory to late antigen-presenting phenotypes, termed early and late plaque-induced gene (PIG) programs. Resilient individuals showed distinct pathological patterns: octogenarians without dementia lacked late PIGs, whereas centenarians showed late PIG activation that was uncoupled from tau accumulation. Together, these findings highlight divergent resilience-associated mechanisms in human aging and position microglial state transitions at the Aβ−tau interface as candidate points of resilience with potential therapeutic relevance.
- 4 June 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (6) , 2047-2059
Top Cited PapersOpen AccessHuman microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience
Alzheimer’s disease (AD) is not an inevitable outcome of pathology but a dynamic process shaped by how brain cells respond to amyloid-β (Aβ) and tau. To disentangle these responses, we combined spatial transcriptomics and single-nucleus RNA sequencing of the superior frontal cortex from octogenarians living with or without dementia and from cognitively intact centenarians with comparable Aβ accumulation. We identified six distinct tissue domains representing a spatial pathological continuum of AD, with a key inflection point marked by a shift from Aβ-associated inflammatory changes to tau-associated cellular programs. This transition was accompanied by a change in microglial states, from early inflammatory to late antigen-presenting phenotypes, termed early and late plaque-induced gene (PIG) programs. Resilient individuals showed distinct pathological patterns: octogenarians without dementia lacked late PIGs, whereas centenarians showed late PIG activation that was uncoupled from tau accumulation. Together, these findings highlight divergent resilience-associated mechanisms in human aging and position microglial state transitions at the Aβ−tau interface as candidate points of resilience with potential therapeutic relevance.
- Open Access
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (3) , e200382
Clinical Clues to the Diagnostic Yield of Genetic Testing in Adults With Late-Onset Behavioral Change
Background and ObjectivesThe diagnosis of behavioral variant frontotemporal dementia is often difficult because behavioral change has a broad differential diagnosis. Genetic testing may aid in the ...
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (3) , e200382
Open AccessClinical Clues to the Diagnostic Yield of Genetic Testing in Adults With Late-Onset Behavioral Change
Background and ObjectivesThe diagnosis of behavioral variant frontotemporal dementia is often difficult because behavioral change has a broad differential diagnosis. Genetic testing may aid in the ...
- Open Access
- 29 May 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (10) , 5879-5888
Assessing the de novo paradigm in sporadic early-onset Alzheimer disease trios
The genetic architecture of sporadic Early-Onset Alzheimer Disease (sEOAD, onset ≤65 years) remains largely unknown. To assess the de novo mutation (DNM) hypothesis, we performed a nationwide recruitment of 37 novel sEOAD patients-unaffected parents trios. After assessing known monogenic genes, we performed trio-based exome sequencing and jointly analyzed novel trios with 12 previously reported ones. Of these, we selected 16 trios for genome sequencing. We identified three patients with a pathogenic DNM in APP or PSEN1. Then, from the 46 remaining trios, we identified 38 non-synonymous coding DNM and 4 de novo copy number variants (CNVs) in exome data. Four DNM (2 novel, in SPHK2 and DDR1) and bi-allelic inherited variants in two genes affected Alzheimer disease-related genes. No significant burden of rare coding variants in exome/genome data from 5643 EOAD cases and 16097 controls was identified using nested windows centered on each DNM position, at the transcript level. From genome data, one non-coding DNM was predicted to affect splicing in an AD-associated gene, PINX1. Overall, 48% probands carried ≥1 inherited risk factor with odds ratio (OR) > 1.5 and GWAS-defined Genetic Risk Scores (GRS) distribution was more consistent with random distribution than enrichment in higher scores in probands. We confirm that DNMs in known monogenic genes explain sEOAD in a minority of cases, while candidate DNMs in other genes might account for a small proportion of additional cases. The majority of sEOAD patients may have a complex etiology including multiple inherited variants, however, GRS might not explain most of its genetic component.
- 29 May 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (10) , 5879-5888
Open AccessAssessing the de novo paradigm in sporadic early-onset Alzheimer disease trios
The genetic architecture of sporadic Early-Onset Alzheimer Disease (sEOAD, onset ≤65 years) remains largely unknown. To assess the de novo mutation (DNM) hypothesis, we performed a nationwide recruitment of 37 novel sEOAD patients-unaffected parents trios. After assessing known monogenic genes, we performed trio-based exome sequencing and jointly analyzed novel trios with 12 previously reported ones. Of these, we selected 16 trios for genome sequencing. We identified three patients with a pathogenic DNM in APP or PSEN1. Then, from the 46 remaining trios, we identified 38 non-synonymous coding DNM and 4 de novo copy number variants (CNVs) in exome data. Four DNM (2 novel, in SPHK2 and DDR1) and bi-allelic inherited variants in two genes affected Alzheimer disease-related genes. No significant burden of rare coding variants in exome/genome data from 5643 EOAD cases and 16097 controls was identified using nested windows centered on each DNM position, at the transcript level. From genome data, one non-coding DNM was predicted to affect splicing in an AD-associated gene, PINX1. Overall, 48% probands carried ≥1 inherited risk factor with odds ratio (OR) > 1.5 and GWAS-defined Genetic Risk Scores (GRS) distribution was more consistent with random distribution than enrichment in higher scores in probands. We confirm that DNMs in known monogenic genes explain sEOAD in a minority of cases, while candidate DNMs in other genes might account for a small proportion of additional cases. The majority of sEOAD patients may have a complex etiology including multiple inherited variants, however, GRS might not explain most of its genetic component.
- Open Access
- 21 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
GWAS meta-analysis of cerebrospinal fluid Alzheimer’s biomarkers reveals loci regulating lipids, brain volume and autophagy
Cerebrospinal fluid amyloid beta 42, total tau, and phosphorylated tau 181 are well accepted markers of Alzheimer’s disease. These biomarkers better reflect disease pathogenesis compared to clinical diagnosis. Here, we perform a genome wide association study meta-analysis including 18,948 individuals of European ancestry and identify 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicate the association of biomarkers with APOE , CR1 , GMNC/CCDC50 and C16orf95/MAP1LC3B . Novel loci include BIN1 for amyloid beta and GNA12, MS4A6A, SLCO1A2 with both total tau and phosphorylated tau 181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2 . We also demonstrate that these variants have significant association with Alzheimer’s disease risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent of APOE , coupled with autophagy and brain volume regulation driven by total tau and phosphorylated tau 181 dysregulation.
- 21 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessGWAS meta-analysis of cerebrospinal fluid Alzheimer’s biomarkers reveals loci regulating lipids, brain volume and autophagy
Cerebrospinal fluid amyloid beta 42, total tau, and phosphorylated tau 181 are well accepted markers of Alzheimer’s disease. These biomarkers better reflect disease pathogenesis compared to clinical diagnosis. Here, we perform a genome wide association study meta-analysis including 18,948 individuals of European ancestry and identify 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicate the association of biomarkers with APOE , CR1 , GMNC/CCDC50 and C16orf95/MAP1LC3B . Novel loci include BIN1 for amyloid beta and GNA12, MS4A6A, SLCO1A2 with both total tau and phosphorylated tau 181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2 . We also demonstrate that these variants have significant association with Alzheimer’s disease risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent of APOE , coupled with autophagy and brain volume regulation driven by total tau and phosphorylated tau 181 dysregulation.
- Open Access
Cognitively Healthy Centenarian Brains resist Tau Accumulation and exhibit lower APOE, early proteasome response and maintained β-oxidation.
Brains from cognitively intact centenarians offer a unique window into mechanisms of neuroprotection. We quantified 3,448 proteins by LC-MS/MS in middle temporal gyrus(MTG) from 88 Alzheimer's disease (AD) patients, 53 controls (50-99 years) and 49 centenarians (100+). After adjustment for cell type composition, Aβ abundance associated with only five proteins, revealing upregulation of HTRA1, LRP1 and NRXN1 as early AD-associated changes. Conversely, tau abundance associated with ~20% of the quantified proteome, revealing GPRIN1 as the top tau-associated protein. One-third of centenarians had high Aβ abundance, often with Braak neurofibrillary tangle stages IV/V, yet all maintained low local tau abundance. Centenarians showed maintained proteostasis (low ubiquitin peptides, high proteasome components), high PCSK1 (prohormone maturation), high PFKFB2 (glycolysis regulation), mitochondria-coupled lipid β-oxidation and lower APOE levels. Together, these findings suggest a model of neuroprotection in which Aβ facilitates tau seeding, and where proteostatic and metabolic adaptations buffer against additional tau accumulation in centenarians.
Open AccessCognitively Healthy Centenarian Brains resist Tau Accumulation and exhibit lower APOE, early proteasome response and maintained β-oxidation.
Brains from cognitively intact centenarians offer a unique window into mechanisms of neuroprotection. We quantified 3,448 proteins by LC-MS/MS in middle temporal gyrus(MTG) from 88 Alzheimer's disease (AD) patients, 53 controls (50-99 years) and 49 centenarians (100+). After adjustment for cell type composition, Aβ abundance associated with only five proteins, revealing upregulation of HTRA1, LRP1 and NRXN1 as early AD-associated changes. Conversely, tau abundance associated with ~20% of the quantified proteome, revealing GPRIN1 as the top tau-associated protein. One-third of centenarians had high Aβ abundance, often with Braak neurofibrillary tangle stages IV/V, yet all maintained low local tau abundance. Centenarians showed maintained proteostasis (low ubiquitin peptides, high proteasome components), high PCSK1 (prohormone maturation), high PFKFB2 (glycolysis regulation), mitochondria-coupled lipid β-oxidation and lower APOE levels. Together, these findings suggest a model of neuroprotection in which Aβ facilitates tau seeding, and where proteostatic and metabolic adaptations buffer against additional tau accumulation in centenarians.
- Open Access
- 22 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Machine learning in Alzheimer’s disease genetics
Traditional statistical approaches have advanced our understanding of the genetics of complex diseases, yet are limited to linear additive models. Here we applied machine learning (ML) to genome-wide data from 41,686 individuals in the largest European consortium on Alzheimer’s disease (AD) to investigate the effectiveness of various ML algorithms in replicating known findings, discovering novel loci, and predicting individuals at risk. We utilised Gradient Boosting Machines (GBMs), biological pathway-informed Neural Networks (NNs), and Model-based Multifactor Dimensionality Reduction (MB-MDR) models. ML approaches successfully captured all genome-wide significant genetic variants identified in the training set and 22% of associations from larger meta-analyses. They highlight 6 novel loci which replicate in an external dataset, including variants which map to ARHGAP25, LY6H, COG7, SOD1 and ZNF597. They further identify novel association in AP4E1, refining the genetic landscape of the known SPPL2A locus. Our results demonstrate that machine learning methods can achieve predictive performance comparable to classical approaches in genetic epidemiology and have the potential to uncover novel loci that remain undetected by traditional GWAS. These insights provide a complementary avenue for advancing the understanding of AD genetics.
- 22 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessMachine learning in Alzheimer’s disease genetics
Traditional statistical approaches have advanced our understanding of the genetics of complex diseases, yet are limited to linear additive models. Here we applied machine learning (ML) to genome-wide data from 41,686 individuals in the largest European consortium on Alzheimer’s disease (AD) to investigate the effectiveness of various ML algorithms in replicating known findings, discovering novel loci, and predicting individuals at risk. We utilised Gradient Boosting Machines (GBMs), biological pathway-informed Neural Networks (NNs), and Model-based Multifactor Dimensionality Reduction (MB-MDR) models. ML approaches successfully captured all genome-wide significant genetic variants identified in the training set and 22% of associations from larger meta-analyses. They highlight 6 novel loci which replicate in an external dataset, including variants which map to ARHGAP25, LY6H, COG7, SOD1 and ZNF597. They further identify novel association in AP4E1, refining the genetic landscape of the known SPPL2A locus. Our results demonstrate that machine learning methods can achieve predictive performance comparable to classical approaches in genetic epidemiology and have the potential to uncover novel loci that remain undetected by traditional GWAS. These insights provide a complementary avenue for advancing the understanding of AD genetics.
- Open Access
- 21 May 2025
- Published by Springer Nature in Research Square
GWAS meta-analysis of CSF Alzheimer's disease biomarkers 18,948 individuals reveal novel loci and genes regulating lipid metabolism, brain volume and autophagy
Cerebrospinal fluid (CSF) amyloid beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau181) are well accepted markers of Alzheimer’s disease. We performed a GWAS meta-analysis including 18,948 individuals of European and 416 non-European ancestry. We identified 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicated the association of CSF biomarkers with APOE, CR1, GMNC/CCDC50 and C16orf95/MAP1LC3B. Novel loci included BIN1 for Aβ42 and GNA12, MS4A6A, SLCO1A2 with both t-tau and p-tau181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2. We also demonstrated that these variants were not only associated with CSF level of the three biomarkers but also showed significant association with AD risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent APOE, as well as autophagy and brain volume regulation driven by t-tau and p-tau181 dysregulation.
- 21 May 2025
- Published by Springer Nature in Research Square
Open AccessGWAS meta-analysis of CSF Alzheimer's disease biomarkers 18,948 individuals reveal novel loci and genes regulating lipid metabolism, brain volume and autophagy
Cerebrospinal fluid (CSF) amyloid beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau181) are well accepted markers of Alzheimer’s disease. We performed a GWAS meta-analysis including 18,948 individuals of European and 416 non-European ancestry. We identified 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicated the association of CSF biomarkers with APOE, CR1, GMNC/CCDC50 and C16orf95/MAP1LC3B. Novel loci included BIN1 for Aβ42 and GNA12, MS4A6A, SLCO1A2 with both t-tau and p-tau181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2. We also demonstrated that these variants were not only associated with CSF level of the three biomarkers but also showed significant association with AD risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent APOE, as well as autophagy and brain volume regulation driven by t-tau and p-tau181 dysregulation.